Nanoparticulate systems for brain delivery of drugs

Advanced Drug Delivery Reviews

Volumn 64, Issue SUPPL., 2012, Pages 213-222

  Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Blood brain barrier; Brain tumors; Drug delivery to the brain; Glioblastomas; Nanoparticles

Indexed keywords

ACTIVE DRUGS; ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN E; BLOOD CAPILLARY; BLOOD PLASMA; BLOOD-BRAIN BARRIER; BRAIN DELIVERY; BRAIN TUMORS; CENTRAL NERVOUS SYSTEMS; DALARGIN; DIPEPTIDE; DOXORUBICIN; DRUG TRANSPORT; GLIOBLASTOMAS; LOPERAMIDE; LOW DENSITY LIPOPROTEINS; NANOPARTICLE SURFACE; NANOPARTICULATE SYSTEM; NEUROPEPTIDES; NMDA RECEPTOR; P-GLYCOPROTEIN; POLYSORBATE 80; POLYSORBATES; TIGHT JUNCTIONS;

ADSORPTION; BLOOD; BRAIN; DRUG DELIVERY; EMULSIONS; ENDOTHELIAL CELLS; MICROCIRCULATION; MOLECULAR BIOLOGY; PEPTIDES; TUMORS;

NANOPARTICLES;

AMITRIPTYLINE; APOLIPOPROTEIN E; CREMOPHOR; DOXORUBICIN; DRUG CARRIER; KYOTORPHIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LOPERAMIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MALTODEXTRIN; MRZ 2 576; MULTIDRUG RESISTANCE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NANOPARTICLE; POLOXAMER; POLY(BUTYL CYANOACRYLATE); POLYSORBATE 80; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BRAIN; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG PENETRATION; DRUG TRANSPORT; ENDOCYTOSIS; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RESPONSE TIME; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS;

EID: 84870238918     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.015     Document Type: Review

References (63)

1. Davson H., Segal M. Physiology of the CSF and Blood-Brain Barrier 1996, CRC Press, Boca Raton, FL, pp. 1-192.
2. Begley D., Kreuter J. Do ultra-low frequency (ULF) magnetic fields affect the blood-brain barrier. Biologic Effects of Light 1998 1999, 297-301. Kluwer Academic Publishers, Boston, MA. M.F. Holick, E.G. Jung (Eds.).
3. Begley D. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 1996, 48:136-146.
4. Brightman M. Ultrastructure of the brain endothelium. Physiology and Pharmacology of the Blood-Brain Barrier. Handbook of Experimental Pharmacology 1992, Vol. 103:1-22. Springer, Berlin. M.W.B. Bradbury (Ed.).
5. Gummerloch M.K., Neuwalt E.A. Drug entry into the brain and its pharmacologic manipulation. Physiology and Pharmacology of the Blood-Brain Barrier. Handbook of Experimental Pharmacology 1992, Vol. 103:525-542. Springer, Berlin. M.W.B. Bradbury (Ed.).
6. Pardridge W.M., Buciak J.L., Friden P.M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 1991, 259:66-70.
7. Zhou X., Huang L. Targeted delivery of DANN by liposomes and polymers. J. Control. Rel. 1992, 19:269-274.
8. Chen D., Lee K.H. Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system. Biochem. Biophys. Acta 1993, 1158:244-250.
9. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 1996, 93:14164-14169.
10. Rapoport S.I. Modulation of the blood-brain barrier permeability. J. Drug Target. 1996, 3:417-425.
11. Dehouck B., Fenart L., Dehouck M.-P., Pierce A., Torpier G., Cecchelli R. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 1997, 138:877-889.
12. Kreuter J. Nanoparticles. Encyclopedia of Pharmaceutical Technology 1994, Vol. 10:165-190. Marcel Dekker, New York. J. Swarbrick, J.C. Boylan (Eds.).
13. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 1983, 15:335-345.
14. Couvreur P., Grislain L., Lenaerts V., Brasseur F., Guiot P., Biernacki A. Biodegradable polymeric nanoparticles and drug carriers for antitumor agents. Polymeric Nanoparticles and Microspheres 1986, 27-93. CRC Press, Boca Raton, FL. P. Guoit, P. Couvreur (Eds.).
15. Alyautdin R., Gothier D., Petrov V., Kharkevich D., Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 1995, 41:44-48.
16. Kreuter J., Alyautdin R.N., Kharkevich D.A., Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995, 674:171-174.
17. Schroeder U., Sabel B.A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 1996, 710:121-124.
18. Ramge P., Kreuter J., Lemmer B. Circadian phase-dependent antinociceptive reaction in mice after i.v. injection of dalargin-loaded nanoparticles determined by the hot-plate test and the tail-flick test. Chronobiol. Int. 1999, 17:767-777.
19. Schroeder U., Sommerfeld P., Ulrich S., Sabel B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 1998, 87:1305-1307.
20. Schroeder U., Sommerfeld P., Sabel B.A. Efficacy of oral dalargin-loaded nanopartcle delivery across the blood-brain barrier. Peptides 1998, 19:777-780.
21. Ramge P. Untersuchungen zur Überwindung der Blut-Hirn-Schranke mit Hilfe von Nanopartikeln 1998, Shaker Verlag, Aachen, pp. 123-139.
22. Olivier J.-C., Fenart L., Chauvet R., Pariat C., Cecchelli R., Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 1999, 16:1836-1842.
23. Castellano C., Puglisi-Allegra S., Renzi P. Genetic differences in daily rhythms of pain sensitivity in mice. Pharmacol. Biochem. Behav. 1985, 23:91-92.
24. Kreuter J., Petrov V.E., Kharkevich D.A., Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Rel. 1997, 49:81-87.
25. Frederickson R.C.A., Burgis V., Edwards J.D. Hyperalgesia induced by naloxone follows diurnal rhythm in responsitivity to painful stimuli. Science 1977, 198:756-758.
26. 3H-labelled dalargin bound to poly(butyl cyanoacrylate nanoparticles) after i.v. injections to mice. Life Sci. 2000, 66:495-502.
27. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997, 14:325-328.
28. Alyautdin R.N., Tezikov E.B., Ramge P., Kharkevich D.A., Begley D.J., Kreuter J. Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 1998, 15:67-74.
29. Friese A., Seiler E., Quack G., Lorenz B., Kreuter J. Enhancement of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacylate) nanoparticles as a parenteral controlled release delivery system. Eur. J. Pharm. Biopharm. 2000, 49:103-109.
30. Friese A. Kleinpartikuläre Trägersysteme (Nanopartikel) als ein parenterales Arzneistofftransportsystem zur Verbesserung der Bioverfügbarkeit ZNS-aktiver Substanzen dargestellt am Beispiel der NMDA-Rezeptor-Antagonisten MRZ 2/576 und MRZ 2/596 2000, Ph.D. Thesis, J.W. Goethe-Universität, Frankfurt.
31. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16:1564-1569.
32. Illum L., Davis S.S. Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J. Pharm. Sci. 1983, 72:1086-1089.
33. Illum L., Davis S.S., Müller R.H., Mak E., West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockcopolymer-poloxamine 908. Life Sci. 1987, 40:367-374.
34. Tröster S.D., Müller U., Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 1990, 61:85-100.
35. Couvreur P., Kante B., Grislain L., Roland M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 1982, 71:790-792.
36. Gelperina S.E., Smirnova Z.S., Khalanskiy A.S., Skidan I.N., Bobruskin A.I., Kreuter J. Chemotherapy of brain tumours using doxorubicin bound to polysorbate 80-coated nanoparticles 2000, Proceedings of the 3rd World Meeting APV/APGI, Berlin, 3/6th April 2000. pp 441-442.
37. Pulfer S.K., Gallo J.M. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J. Drug Target. 1998, 6:215-227.
38. Borchard G., Audus K.L., Shi F., Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 1994, 110:29-35.
39. R.N. Alyautdin, A. Reichel, R. Löbenberg, P. Ramge, J. Kreuter, D.J. Begley, Interaction of poly-(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro, J. Drug Target (2001) in press.
40. Ramge P., Unger R.E., Oltrogge J.B., Begley D., von Briesen H., Kreuter J. Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human, bovine and murine primary brain capilary endothelial cells. Eur. J. Neuro. 2000, 12:1935-1940.
41. Ramge P. Untersuchungen zur Überwindung der Blut-Hirn-Schranke mit Hilfe von Nanopartikeln 1998, Shaker Verlag, Aachen, pp. 99-110.
42. Ramge P. Untersuchungen zur Überwindung der Blut-Hirn-Schranke mit Hilfe von Nanopartikeln 1998, Shaker Verlag, Aachen, pp. 93-98.
43. Ramge P. Untersuchungen zur Überwindung der Blut-Hirn-Schranke mit Hilfe von Nanopartikeln 1998, Shaker Verlag, Aachen, pp. 111-118.
44. Steiniger S., Zenker D., von Briesen H., Begley D., Kreuter J. The influence of polysorbate 80-coated nanoparticles on bovine brain capillary endothelial cells in vitro. Proc. Int. Symp. Control. Rel. Bioact. Mater. 1999, 26:789-790.
45. Dehouck N.P., Méresse S., Delorme P., Fruchart J.C., Cecchelli R. An easier, reproducible, and mass-production method to study the blood brain barrier in vitro. J. Neurochem. 1990, 54:1798-1801.
46. Dehouck M.P., Jolliet-Riant P., Brée F., Fruchart J.C., Cecchelli R., Tillement J.P. Drug transfer across the blood-brain barrier: Correlation between in vitro and in vivo models. J. Neurochem. 1992, 58:1790-1797.
47. Fenart L., Casanova A., Dehouck B., Duhem C., Slupek S., Cecchelli R., Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 1999, 291:1017-1022.
48. 14C in the rat. Am. J. Physiol. 1971, 221:214-217.
49. Fenstermacher J.D., Patlak C.S. The exchange of materials between cerebrospinal fluid and brain. Fluid Environment of the Brain 1975, Academic Press, New York. H.F. Cserr, J.D. Fenstermacher, V. Fencl (Eds.).
50. Kessler J.A., Fenstermacher J.D., Owens E.S. Spinal subarachnoid perfusion of rhesus monkeys. Am. J. Physiol. 1976, 230:614-618.
51. Cremer J.E., Seville M.P. Regional brain blood low, blood volume, and haematocrit values the adult rat. J. Cereb. Blood Flow Metab. 1983, 3:254-256.
52. Fenstermacher J.D., Gross P., Sposito N., Acuff V., Pettersen S., Gruber K. Structural and functional variations in capillary systems within the brain. Ann. N.Y. Acad. Sci. 1988, 529:21-30.
53. Lück M. Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern 1997, Ph.D. Thesis, Freie Universität, Berlin, pp. 14-24 and 137-154.
54. Méresse S., Delbart C., Fruchart J.G., Cecchelli R. Low-density lipoprotein receptor on endothelium of brain capillaries. J. Neurochem. 1989, 53:340-345.
55. De Vries H.E., Kuiper J., de Boer A.G., van Berkel T.J., Breimer D.D. Characterization of the scavenger receptor on bovine cerebral endothelial cells in vitro. J. Neurochem. 1993, 61:1813-1821.
56. Dehouck B., Dehouck M.P., Fruchart J.C., Cecchelli R. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J. Cell Biol. 1994, 126:465-473.
57. Lucarelli M., Gennarelli M., Cardelli P., Novelli G., Scarpa S., Dallapicolla B., Strom R. Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. FEBS Lett. 1997, 401:53-58.
58. Cecchelli R., Fenart L., Descamps L., Torpier G., Dehouck M.P. Receptor-mediated transcytosis of blood-borne molecules through blood-brain barrier endothelial cells: Drug targeting by endogenous transport routes. Proc. Intl. Symp. Control. Rel. Bioact. Mater. 1997, 24:221-222.
59. Pitas R.E., Boyles J.K., Lee D.H., Foss D., Maley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochem. Biophys. Acta 1987, 917:148-161.
60. Woodcock D.M., Linsenmeyer M.E., Chrojnowski G., Kriegler A.B., Nink V., Webster L.K., Sawyer W.H. Reversal of multidrug resistance by surfactants. Br. J. Cancer. 1992, 66:62-68.
61. Nerurkar M.M., Burto P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 1996, 13:528-534.
62. Cordon-Cardo C., O'Brien J.P., Casals D., Rittmann-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 1989, 86:695-698.
63. Kattan J., Droz J.-P., Couvreur P., Marino J.-P., Boutan-Laroze A., Rougier P., Brault P., Vranckx H., Grognet J.-M., Morge X., Sancho-Garnier H. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by poly(isohexyl cyanoacrylate) nanoparticles. Invest. New Drugs 1992, 10:191-199.